Acute kidney injury in patients with severe COVID-19 in Mexico

Autor: Mauricio González-Navarro, Christopher E. Ormsby, Santiago Ávila-Ríos, Claudia Alvarado-de la Barrera, Isabel León-Rodríguez, Amy B. Peralta-Prado, Yara Luna-Villalobos, Alejandro Velasco-Morales, Natalia Calderón-Dávila, Gustavo A. Casas-Aparicio
Rok vydání: 2021
Předmět:
Male
RNA viruses
Viral Diseases
Pulmonology
Physiology
Epidemiology
Coronaviruses
medicine.medical_treatment
Kaplan-Meier Estimate
030204 cardiovascular system & hematology
urologic and male genital diseases
Body Mass Index
Medical Conditions
0302 clinical medicine
Furosemide
Risk Factors
Medicine and Health Sciences
030212 general & internal medicine
Stage (cooking)
Pathology and laboratory medicine
Virus Testing
Multidisciplinary
Medical record
Acute kidney injury
Acute Kidney Injury
Middle Aged
Medical microbiology
female genital diseases and pregnancy complications
Infectious Diseases
Physiological Parameters
Viruses
Cohort
Medicine
Female
Anatomy
SARS CoV 2
Pathogens
Research Article
medicine.drug
medicine.medical_specialty
SARS coronavirus
Science
Microbiology
03 medical and health sciences
Diagnostic Medicine
Internal medicine
medicine
Humans
Obesity
Mexico
Inflammation
Mechanical ventilation
SARS-CoV-2
business.industry
Body Weight
Organisms
Viral pathogens
COVID-19
Biology and Life Sciences
Covid 19
Kidneys
Renal System
Pneumonia
medicine.disease
Microbial pathogens
ROC Curve
Medical Risk Factors
business
Body mass index
Biomarkers
Zdroj: PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0246595 (2021)
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0246595
Popis: Introduction Some patients with COVID-19 pneumonia present systemic disease involving multiple systems. There is limited information about the clinical characteristics and events leading to acute kidney injury (AKI). We described the factors associated with the development of AKI and explored the relation of AKI and mortality in Mexican population with severe COVID-19. Methods We retrospectively reviewed the medical records of individuals with severe pneumonia caused by SARS-CoV-2 hospitalized at the largest third-level reference institution for COVID-19 care in Mexico between March and April 2020. Demographic information, comorbidities, clinical and laboratory data, dates of invasive mechanical ventilation (IMV) and hospitalization, mechanical-ventilator settings and use of vasoactive drugs were recorded. Results Of 99 patients studied, 58 developed AKI (58.6%). The risk factors for AKI were older age (OR = 1.07, 95% CI = 1.01–1.13, p = 0.024); obesity (OR = 6.58, 95% CI = 1.8–24.05, p = 0.040); and the need for IMV (OR = 6.18, CI = 1.29–29.58, p = 0.023). The risk factors for mortality were obesity (OR = 5.57, 95% CI = 1.48–20.93, p = 0.011); requirement of vasoactive drugs on admission (OR = 5.35, 95% CI = 1.16–24.61, p = 0.031); and AKI (OR = 8.61, 95% CI = 2.24–33.1, p = 0.002). In-hospital mortality was significantly higher in patients with AKI stage 3 (79.3%) and AKI stage 2 (68.7%) compared with those with AKI stage 1 (25%; p = 0.004). Fifty-three patients underwent the furosemide stress test (FST) to predict progression to AKI stage 3. Of those, 12 progressed to AKI stage 3 (22%). The ROC curve for the FST had an AUC of 0.681 (p = 0.009); a sensitivity of 81.6% and a specificity of 54.5%. Conclusions AKI was common in our cohort of patients with severe pneumonia caused by SARS-CoV-2 infection. The risk factors for AKI were older age, obesity and the need for of IMV on admission. The risk factors for mortality were obesity, requirement of vasoactive drugs on admission and AKI. Mortality was more frequent in patients with AKI stages 2–3. The FST had an acceptable predictive capacity to identify patients progressing to AKI stage 3.
Databáze: OpenAIRE